Recent Update of Clinical Drug Trials in Alzheimer's Disease
Journal of the Korean Neurological Association
;
: 252-258, 2015.
Article
in Korean
| WPRIM
| ID: wpr-39327
ABSTRACT
The prevalence of Alzheimer's disease (AD) is increasing as the global population ages. Currently available treatments for AD target cholinergic and glutamatergic neurotransmission. There have been modest symptomatic effects, but disease modifying effects have not been accomplished. This is even true of clinical trials of bapineuzumab and solanezumab, two humanized monoclonal antibodies that bind amyloid. Therefore, innovations in clinical trial designs are necessary, including revised diagnostic criteria and treatment at the earliest stages of AD. Several prevention trials started in 2013, emphasizing these innovative principles of clinical trial design. In this review, we will discuss the paradigm shift for AD clinical treatment trials and ongoing preventative trials.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prevalence
/
Synaptic Transmission
/
Alzheimer Disease
/
Amyloid
/
Antibodies, Monoclonal
Type of study:
Prevalence study
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Neurological Association
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS